Hans Schreiber mainly focuses on Immunology, Antigen, Cancer research, Stromal cell and Cancer cell. In most of his Immunology studies, his work intersects topics such as Cancer. His study in Antigen is interdisciplinary in nature, drawing from both Molecular biology, Monoclonal antibody and T cell.
His research in Cancer research intersects with topics in Tumor progression, Chemotaxis, Tumor antigen and In vivo. The Stromal cell study which covers Bone marrow that intersects with Breast cancer, Epithelioma, Metastasis and Carcinoma. The concepts of his Cancer cell study are interwoven with issues in Cytotoxic T cell and Virology.
His main research concerns Immunology, Antigen, Cancer research, Immune system and Cancer. The study incorporates disciplines such as Cancer cell and Cytotoxic T cell in addition to Immunology. He combines subjects such as Molecular biology, Antibody and Tumor antigen with his study of Antigen.
As a part of the same scientific family, Hans Schreiber mostly works in the field of Cancer research, focusing on In vitro and, on occasion, Virology. His work carried out in the field of Immune system brings together such families of science as Tumor progression and Fibrosarcoma. In his study, Respiratory tract is inextricably linked to Pathology, which falls within the broad field of Cancer.
Hans Schreiber mainly investigates Cancer research, Immunology, Cancer, Antigen and T cell. He has included themes like Cancer cell, Interleukin 21 and Tumor antigen in his Cancer research study. His Immunology study frequently links to other fields, such as Macrophage.
His work in Cancer covers topics such as Adoptive cell transfer which are related to areas like Mutation. His work carried out in the field of Antigen brings together such families of science as Cell biology, Chimeric antigen receptor and T-cell receptor. He has researched T cell in several fields, including Cytotoxic T cell, Cell culture and Vaccination.
The scientist’s investigation covers issues in Immunology, Cancer research, Cancer, Antigen and Cancer cell. His study in T cell and Interferon is carried out as part of his studies in Immunology. Hans Schreiber specializes in Cancer research, namely Tumor microenvironment.
Hans Schreiber combines subjects such as Cytotoxic T cell and Interleukin 21 with his study of Tumor microenvironment. His research in Antigen intersects with topics in Tn antigen, Chimeric antigen receptor and Immune system. His biological study deals with issues like Stromal cell, which deal with fields such as Paracrine Communication and Tumor growth.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski;Hans Schreiber;Yang Xin Fu.
Nature Immunology (2013)
The terminology issue for myeloid-derived suppressor cells.
Dmitry I. Gabrilovich;Vincenzo Bronte;Shu Hsia Chen;Mario P. Colombo.
Cancer Research (2007)
Inflammation as a tumor promoter in cancer induction.
Mary Philip;Donald A. Rowley;Hans Schreiber.
Seminars in Cancer Biology (2004)
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors
Ping Yu;Youjin Lee;Wenhua Liu;Thomas Krausz.
Journal of Experimental Medicine (2005)
Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction.
Markus Gerhard;Hartmut Juhl;Holger Kalthoff;Hans W. Schreiber.
Journal of Clinical Oncology (1994)
A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.
G Torre-Amione;R D Beauchamp;H Koeppen;B H Park.
Proceedings of the National Academy of Sciences of the United States of America (1990)
CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
Dominik Mumberg;Paul A. Monach;Sherry Wanderling;Mary Philip.
Proceedings of the National Academy of Sciences of the United States of America (1999)
Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.
J L Urban;H M Shepard;J L Rothstein;B J Sugarman.
Proceedings of the National Academy of Sciences of the United States of America (1986)
Classification of current anticancer immunotherapies
Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué.
Inhibition of tumor growth by elimination of granulocytes.
Lisa A. Pekarek;Barbara A. Starr;Alicia Y. Toledano;Hans Schreiber.
Journal of Experimental Medicine (1995)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: